Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

304 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Novel agents improve survival of transplant patients with multiple myeloma including those with high-risk disease defined by early relapse (<12 months).
Venner CP, Connors JM, Sutherland HJ, Shepherd JD, Hamata L, Mourad YA, Barnett MJ, Broady R, Forrest DL, Hogge DE, Nantel SH, Narayanan S, Nevill TJ, Nitta J, Power MM, Toze CL, Smith CA, Song KW. Venner CP, et al. Among authors: barnett mj. Leuk Lymphoma. 2011 Jan;52(1):34-41. doi: 10.3109/10428194.2010.531409. Epub 2010 Dec 6. Leuk Lymphoma. 2011. PMID: 21133716
Comparison of a pediatric-inspired treatment protocol versus standard-intensity chemotherapy for young adults with standard-risk BCR-ABL negative acute lymphoblastic leukemia.
Kliman D, Barnett M, Broady R, Forrest D, Gerrie A, Hogge D, Nantel S, Narayanan S, Nevill T, Power M, Sanford D, Song K, Sutherland H, Toze C, Abou Mourad Y. Kliman D, et al. Leuk Lymphoma. 2017 Apr;58(4):909-915. doi: 10.1080/10428194.2016.1222376. Epub 2016 Aug 26. Leuk Lymphoma. 2017. PMID: 27561638
Long-term outcome of myeloablative allogeneic stem cell transplantation for multiple myeloma.
Kuruvilla J, Shepherd JD, Sutherland HJ, Nevill TJ, Nitta J, Le A, Forrest DL, Hogge DE, Lavoie JC, Nantel SH, Toze CL, Smith CA, Barnett MJ, Song KW. Kuruvilla J, et al. Among authors: barnett mj. Biol Blood Marrow Transplant. 2007 Aug;13(8):925-31. doi: 10.1016/j.bbmt.2007.04.006. Epub 2007 May 29. Biol Blood Marrow Transplant. 2007. PMID: 17640596 Free article. Clinical Trial.
High-dose chemotherapy and autologous stem cell transplantation for primary refractory or relapsed Hodgkin lymphoma: long-term outcome in the first 100 patients treated in Vancouver.
Lavoie JC, Connors JM, Phillips GL, Reece DE, Barnett MJ, Forrest DL, Gascoyne RD, Hogge DE, Nantel SH, Shepherd JD, Smith CA, Song KW, Sutherland HJ, Toze CL, Voss NJ, Nevill TJ. Lavoie JC, et al. Among authors: barnett mj. Blood. 2005 Aug 15;106(4):1473-8. doi: 10.1182/blood-2004-12-4689. Epub 2005 May 3. Blood. 2005. PMID: 15870180 Free article.
Allogeneic haematopoietic stem-cell transplantation for relapsed and refractory aggressive histology non-Hodgkin lymphoma.
Doocey RT, Toze CL, Connors JM, Nevill TJ, Gascoyne RD, Barnett MJ, Forrest DL, Hogge DE, Lavoie JC, Nantel SH, Shepherd JD, Sutherland HJ, Voss NJ, Smith CA, Song KW. Doocey RT, et al. Among authors: barnett mj. Br J Haematol. 2005 Oct;131(2):223-30. doi: 10.1111/j.1365-2141.2005.05755.x. Br J Haematol. 2005. PMID: 16197454 Free article.
High-dose therapy and autologous hematopoietic stem-cell transplantation does not increase the risk of second neoplasms for patients with Hodgkin's lymphoma: a comparison of conventional therapy alone versus conventional therapy followed by autologous hematopoietic stem-cell transplantation.
Forrest DL, Hogge DE, Nevill TJ, Nantel SH, Barnett MJ, Shepherd JD, Sutherland HJ, Toze CL, Smith CA, Lavoie JC, Song KW, Voss NJ, Gascoyne RD, Connors JM. Forrest DL, et al. Among authors: barnett mj. J Clin Oncol. 2005 Nov 1;23(31):7994-8002. doi: 10.1200/JCO.2005.01.9083. Epub 2005 Oct 3. J Clin Oncol. 2005. PMID: 16204014
IPSS poor-risk karyotype as a predictor of outcome for patients with myelodysplastic syndrome following myeloablative stem cell transplantation.
Nevill TJ, Shepherd JD, Sutherland HJ, Abou Mourad YR, Lavoie JC, Barnett MJ, Nantel SH, Toze CL, Hogge DE, Forrest DL, Song KW, Power MM, Nitta JY, Dai Y, Smith CA. Nevill TJ, et al. Among authors: barnett mj. Biol Blood Marrow Transplant. 2009 Feb;15(2):205-13. doi: 10.1016/j.bbmt.2008.11.015. Biol Blood Marrow Transplant. 2009. PMID: 19167680 Free article.
Response to tyrosine kinase inhibitor therapy in patients with chronic myelogenous leukemia relapsing in chronic and advanced phase following allogeneic hematopoietic stem cell transplantation.
Wright MP, Shepherd JD, Barnett MJ, Nantel SH, Sutherland HJ, Toze CL, Hogge DE, Nevill TJ, Song KW, Abou Mourad YR, Narayanan S, Power MM, Smith CA, Forrest DL. Wright MP, et al. Among authors: barnett mj. Biol Blood Marrow Transplant. 2010 May;16(5):639-46. doi: 10.1016/j.bbmt.2009.11.026. Epub 2010 Feb 4. Biol Blood Marrow Transplant. 2010. PMID: 20005967 Free article.
Long-term follow-up of patients with chronic myeloid leukemia in chronic phase developing sudden blast phase on imatinib therapy.
Tantiworawit A, Power MM, Barnett MJ, Hogge DE, Nantel SH, Nevill TJ, Shepherd JD, Song KW, Sutherland HJ, Toze CL, Abou-Mourad YR, Narayanan S, Broady RC, Forrest DL. Tantiworawit A, et al. Among authors: barnett mj. Leuk Lymphoma. 2012 Jul;53(7):1321-6. doi: 10.3109/10428194.2011.652108. Epub 2012 Mar 5. Leuk Lymphoma. 2012. PMID: 22192245
304 results